Literature DB >> 26239720

Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.

Hideo Komita1, Shigeo Koido1, Kazumi Hayashi2, Shin Kan2, Masaki Ito2, Yuko Kamata2, Masafumi Suzuki3, Sadamu Homma2.   

Abstract

Monoclonal antibody therapy for immune checkpoint blockade has achieved promising results for several types of malignant tumors. For the future treatment of gastrointestinal stromal tumors (GISTs) by immune checkpoint blockade, expression of immune checkpoint-related molecules that suppress antitumor immunity in GISTs was examined. Infiltration of immune cell types into 19 GIST tissues was analyzed by immunohistochemistry, and expression of T cell immunoglobulin and mucin protein 3 (Tim-3) and programmed cell death-1 (PD-1) in the infiltrated immune cells was examined by immunofluorescence microscopy. The expression status of galectin-9 in the GIST tumor cells was also determined by immunohistochemistry. All the GIST tissues showed CD8+ T cell infiltration and 8 showed CD56+ natural killer (NK) cell infiltration, and the numbers of infiltrated CD8+ T and NK cells were strongly correlated. However, these CD8+ T and NK cells were CD69-negative inactivated cells. Tim-3 was expressed in the infiltrated NK cells in 6/8 (75%) of the GIST tissues. Expression of galectin-9, a ligand of Tim-3, was observed in 13/19 (68.4%) GIST tissues and all of the GIST tissues with Tim-3+ NK cell infiltration showed positive galectin-9 expression. No PD-1 expression in the infiltrated NK cells and neither Tim-3 nor PD-1 expression was observed in the infiltrated CD8+ T cells. Interaction between Tim-3 in infiltrated NK cells and galectin-9 in tumor cells may be involved in an immune checkpoint mechanism for suppression of antitumor immunity in GISTs. Blockade of the Tim-3/galectin-9 pathway may become a new strategy for GIST treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239720     DOI: 10.3892/or.2015.4149

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  21 in total

Review 1.  Current status of immunotherapy for gastrointestinal stromal tumor.

Authors:  Y Tan; J C Trent; B A Wilky; D A Kerr; A E Rosenberg
Journal:  Cancer Gene Ther       Date:  2017-02-10       Impact factor: 5.987

Review 2.  Galectin-9: From cell biology to complex disease dynamics.

Authors:  Sebastian John; Rashmi Mishra
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

Review 3.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

4.  The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.

Authors:  Sashi Kandel; Pratik Adhikary; Guangfu Li; Kun Cheng
Journal:  Cancer Lett       Date:  2021-04-22       Impact factor: 9.756

5.  Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.

Authors:  F Solorzano-Ibarra; A G Alejandre-Gonzalez; P C Ortiz-Lazareno; B E Bastidas-Ramirez; A Zepeda-Moreno; M C Tellez-Bañuelos; N Banu; O J Carrillo-Garibaldi; A Chavira-Alvarado; M R Bueno-Topete; S Del Toro-Arreola; J Haramati
Journal:  Clin Exp Immunol       Date:  2021-01-18       Impact factor: 5.732

Review 6.  Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.

Authors:  Hyung-Joon Kwon; Nayoung Kim; Hun Sik Kim
Journal:  Exp Mol Med       Date:  2017-03-31       Impact factor: 8.718

Review 7.  Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials.

Authors:  Daniel Compagno; Carolina Tiraboschi; José Daniel Garcia; Yorfer Rondón; Enrique Corapi; Carla Velazquez; Diego José Laderach
Journal:  Biomolecules       Date:  2020-05-12

Review 8.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

Review 9.  NK Cell-Based Immune Checkpoint Inhibition.

Authors:  Muhammad Khan; Sumbal Arooj; Hua Wang
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

Review 10.  Harnessing NK Cells for Cancer Treatment.

Authors:  Paola Minetto; Fabio Guolo; Silvia Pesce; Marco Greppi; Valentina Obino; Elisa Ferretti; Simona Sivori; Carlo Genova; Roberto Massimo Lemoli; Emanuela Marcenaro
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.